| Literature DB >> 34367063 |
Xiaoyun Yang1,2, Qian Liu1, Yuxin Fan1, Li Ding1, Ruodan Wang1, Gang Hu2, Ming Liu1.
Abstract
Background: Controlling blood glucose, blood pressure, and blood lipid is of great importance for patients with type 2 diabetes, not only for cardiovascular disease, but also for other complications. Previous studies mainly focused on the control rate of outpatients, and the results were suboptimal, but few studies aimed at the inpatients. Method: The present study involved 3,245 hospitalized patients with type 2 diabetes from 2013 to 2017 in the Department of Endocrinology and Metabolism of Tianjin Medical University General Hospital. The percentages of inpatients who attained the goals of the China Diabetes Society and the American Diabetes Association were calculated for major cardiovascular risk factors (HbA1c, blood pressure, and blood lipid). The prevalence of microvascular and macrovascular complications was also assessed. Result: The percentages of patients who met the Chinese Diabetes Society goals-HbA1c <7%, blood pressure <130/80 mmHg, normal lipids, and all three goals-were 26.7, 14.8, 10.4, and 0.2% in 2013 and 30.5, 16.2, 8.0, and 0.9% in 2017, respectively. The percentage of patients who met all three American Diabetes Association goals (HbA1c<7%, blood pressure <140/90 mmHg, low-density lipoprotein cholesterol <2.6 mmol/L) increased from 4.3% in 2013 to 9.0% in 2017. The prevalence of major diabetes complications including coronary heart disease (31.7 vs. 31.9%), stroke (16.7 vs. 14.8%), diabetic kidney disease (37.9 vs. 35.8%), diabetic retinopathy (48.0 vs. 46.5%), neuropathy (63.1 vs. 61.9%), and diabetic foot (0.8 vs. 1.2%) were stable from 2013 to 2017.Entities:
Keywords: cardiovascular risk factors; complications; control rates; prevalence; type 2 diabetes
Mesh:
Substances:
Year: 2021 PMID: 34367063 PMCID: PMC8339370 DOI: 10.3389/fendo.2021.664183
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Participant flow chart.
Baseline characteristics of inpatients with type 2 diabetes.
| Average | Men | Women | P value | |
|---|---|---|---|---|
| No. of participants | 3245 | 1545 | 1700 | |
| Age, years | 59.2 (12.1) | 57.7 (11.9) | 60.6 (12.1) | 0.00 |
| Body mass index, kg/m2 | 26.5 (4.15) | 26.4 (3.67) | 26.6 (4.54) | 0.16 |
| Blood pressure, mmHg | ||||
| Systolic | 136 (19.1) | 136 (18.5) | 137 (19.6) | 0.44 |
| Diastolic | 81.0 (11.0) | 82.4 (11.2) | 79.8 (10.7) | 0.00 |
| Total cholesterol, mmol/L | 4.93 (1.46) | 4.71 (1.39) | 5.12 (1.50) | 0.00 |
| High-density lipoprotein cholesterol, mmol/L | 1.15 (0.37) | 1.06 (0.34) | 1.23 (0.38) | 0.00 |
| Low-density lipoprotein cholesterol, mmol/L | 2.95 (1.13) | 2.81 (0.99) | 3.08 (1.24) | 0.00 |
| Triglycerides, mmol/L | 1.50 (1.20) | 1.49 (1.26) | 1.51 (1.16) | 0.40 |
| HbA1c, % | 8.34 (2.00) | 8.38 (2.01) | 8.30 (1.99) | 0.09 |
| HBA1c, mmol/moL | 67.6 (21.9) | 68.1 (22.0) | 67.2 (21.7) | 0.93 |
| Uses of medication, % | ||||
| Antihypertensive medication | 53.3 | 51.0 | 55.3 | 0.02 |
| Glucose-lowering medication | 96.5 | 97.0 | 96.1 | 0.16 |
| Oral hypoglycemic agents | 33.4 | 32.9 | 33.9 | 0.55 |
| Insulin | 63.2 | 64.2 | 62.3 | 0.26 |
| Lipid-lowering medication | 44.3 | 43.7 | 44.8 | 0.52 |
Data are mean (SD) or percentage.
Percentage of inpatients with type 2 diabetes attaining the Chinese Diabetes Society goals for Prevention and Treatment of Diabetes from 2013 to 2017.
| Year | P value | |||||
|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | ||
| No. of participants | ||||||
| Men | 259 | 281 | 275 | 346 | 384 | |
| Women | 348 | 321 | 264 | 393 | 374 | |
| Total | 607 | 602 | 539 | 739 | 758 | |
| HbA1c <7.0% | ||||||
| Men | 26.2 | 24.9 | 29.9 | 24.2 | 29.9 | 0.299 |
| Women | 27.3 | 24.3 | 26.5 | 36.4 | 31.0 | 0.004 |
| Average | 26.7 | 24.6 | 28.3 | 30.7 | 30.5 | 0.065 |
| Blood pressure <130/80 mmHg | ||||||
| Men | 14.3 | 14.6 | 13.1 | 19.1 | 14.8 | 0.270 |
| Women | 15.6 | 18.3 | 23.1 | 24.0 | 17.5 | 0.017 |
| Average | 14.8 | 16.6 | 18.1 | 21.7 | 16.3 | 0.011 |
| Normal lipids | ||||||
| Men | 16.6 | 10.6 | 9.20 | 16.7 | 10.6 | 0.007 |
| Women | 5.20 | 4.70 | 8.30 | 7.90 | 5.60 | 0.192 |
| Average | 10.4 | 7.50 | 8.50 | 12.1 | 8.00 | 0.019 |
| Triglyceride <1.7 mmol/L | ||||||
| Men | 61.0 | 56.4 | 61.6 | 61.7 | 54.0 | 0.120 |
| Women | 59.9 | 61.2 | 61.3 | 61.6 | 52.4 | 0.053 |
| Average | 60.3 | 59.0 | 61.4 | 61.7 | 53.3 | 0.006 |
| Total cholesterol <4.5 mmol/L | ||||||
| Men | 43.6 | 46.5 | 54.1 | 49.9 | 43.4 | 0.038 |
| Women | 29.9 | 31.1 | 34.1 | 40.0 | 34.2 | 0.040 |
| Average | 36.4 | 38.5 | 43.8 | 44.7 | 38.6 | 0.006 |
| Low-density lipoprotein cholesterol <2.6 mmol/L (without CHD)/<1.8 mmol/L (with CHD) | ||||||
| Men | 35.9 | 34.9 | 38.6 | 38.4 | 37.7 | 0.854 |
| Women | 22.3 | 21.7 | 29.2 | 34.5 | 28.9 | <0.001 |
| Average | 28.5 | 28.0 | 33.6 | 36.4 | 33.2 | 0.004 |
| High-density lipoprotein cholesterol >1.0 mmol/L (men)/>1.3 mmol/L (women) | ||||||
| Men | 62.9 | 47.3 | 39.1 | 44.5 | 50.2 | <0.001 |
| Women | 39.1 | 32.1 | 36.4 | 35.9 | 29.4 | 0.061 |
| Average | 49.9 | 39.3 | 37.2 | 40.0 | 39.6 | <0.001 |
| All three | ||||||
| Men | 0.05 | 0.7 | 1.5 | 1.7 | 0.5 | 0.151 |
| Women | 0.3 | 0 | 0.4 | 0.5 | 1.3 | 0.149 |
| Average | 0.2 | 0.3 | 0.9 | 1.1 | 0.9 | 0.211 |
Values are adjusted for age and sex (total samples analyses only).
Percentage of inpatients with type 2 diabetes attaining the American Diabetes Association goals of cardiovascular risk factors from 2013 to 2017.
| Year | P value | |||||
|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | ||
| No. of participants | ||||||
| Men | 259 | 281 | 275 | 346 | 384 | |
| Women | 348 | 321 | 264 | 393 | 374 | |
| Total | 607 | 602 | 539 | 739 | 758 | |
| HbA1c <7.0% | ||||||
| Men | 26.2 | 24.9 | 29.9 | 24.2 | 29.9 | 0.299 |
| Women | 27.3 | 24.3 | 26.5 | 36.4 | 31.0 | 0.004 |
| Average | 26.7 | 24.6 | 28.3 | 30.7 | 30.6 | 0.065 |
| Blood pressure <140/90 mmHg | ||||||
| Men | 41.7 | 49.8 | 54.5 | 50.6 | 50.0 | 0.056 |
| Women | 48.7 | 45.7 | 56.1 | 50.5 | 46.6 | 0.089 |
| Average | 45.7 | 47.7 | 55.2 | 50.6 | 48.4 | 0.017 |
| Low-density lipoprotein cholesterol <2.6 mmol/L | ||||||
| Men | 41.3 | 40.5 | 47.1 | 45.0 | 45.0 | 0.471 |
| Women | 31.4 | 31.7 | 38.6 | 40.5 | 37.6 | 0.033 |
| Average | 36.0 | 36.0 | 42.6 | 42.7 | 41.2 | 0.014 |
| All three | ||||||
| Men | 3.9 | 6.4 | 10.6 | 7.8 | 8.3 | 0.047 |
| Women | 4.6 | 5.3 | 6.8 | 8.2 | 9.5 | 0.058 |
| Average | 4.3 | 5.8 | 8.7 | 8.0 | 9.0 | 0.004 |
Values are adjusted for age and sex (total samples analyses only).
Prevalence of major diabetic complications among inpatients with type 2 diabetes in Tianjin General Hospital from 2013 to 2017.
| Year | P value | |||||
|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | ||
| No. of participants | ||||||
| Men | 259 | 281 | 275 | 346 | 384 | |
| Women | 348 | 321 | 264 | 393 | 374 | |
| Total | 607 | 602 | 539 | 739 | 758 | |
| Coronary heart disease | ||||||
| Men | 35.9 | 29.2 | 25.8 | 30.1 | 35.2 | 0.041 |
| Women | 28.1 | 27.1 | 29.2 | 22.1 | 29.0 | 0.167 |
| Average | 31.7 | 28.1 | 27.3 | 25.9 | 31.9 | 0.044 |
| Stroke | ||||||
| Men | 18.9 | 16.7 | 16.4 | 15.0 | 13.8 | 0.491 |
| Women | 14.9 | 16.8 | 16.3 | 12.4 | 15.8 | 0.498 |
| Average | 16.7 | 16.8 | 16.3 | 13.7 | 14.8 | 0.420 |
| Diabetic kidney disease | ||||||
| Men | 45.9 | 42.0 | 35.7 | 41.6 | 38.5 | 0.144 |
| Women | 31.3 | 35.9 | 39.4 | 30.0 | 33.5 | 0.098 |
| Average | 37.9 | 38.8 | 37.3 | 35.5 | 35.8 | 0.695 |
| Diabetic retinopathy | ||||||
| Men | 50.6 | 50.9 | 50.2 | 45.4 | 46.6 | 0.509 |
| Women | 46.0 | 51.1 | 46.2 | 43.2 | 46.6 | 0.346 |
| Average | 48.0 | 51.0 | 48.2 | 44.3 | 46.5 | 0.161 |
| Neuropathy | ||||||
| Men | 69.5 | 67.3 | 63.2 | 63.6 | 65.1 | 0.488 |
| Women | 57.7 | 59.9 | 57.2 | 58.9 | 59.2 | 0.960 |
| Average | 63.1 | 63.4 | 60.1 | 61.2 | 61.9 | 0.767 |
| Diabetic foot | ||||||
| Men | 0 | 0.05 | 0 | 0.30 | 1.00 | 0.065 |
| Women | 1.40 | 0.60 | 1.10 | 0.80 | 1.30 | 0.796 |
| Average | 0.80 | 0.3 | 0.60 | 0.50 | 1.20 | 0.349 |
Values are adjusted for age and sex (total samples analyses only).
Percentage of uses of medication from 2013 to 2017 among inpatients with type 2 diabetes.
| Year | P value | |||||
|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | ||
| No. of participants | ||||||
| Men | 259 | 281 | 275 | 346 | 384 | |
| Women | 348 | 321 | 264 | 393 | 374 | |
| Total | 607 | 602 | 539 | 739 | 758 | |
| Uses of antihypertensive medication | ||||||
| Men | 56.0 | 50.1 | 46.7 | 51.1 | 51.2 | 0.310 |
| Women | 57.9 | 57.0 | 47.6 | 56.0 | 56.0 | 0.080 |
| Average | 56.9 | 53.7 | 47.4 | 53.8 | 53.7 | 0.023 |
| Uses of lipid-lowering medication | ||||||
| Men | 43.6 | 39.5 | 38.2 | 46.2 | 48.4 | 0.043 |
| Women | 44.9 | 43.5 | 41.2 | 42.5 | 50.9 | 0.088 |
| Average | 44.3 | 41.5 | 39.8 | 44.3 | 49.6 | 0.004 |
| Uses of Glucose-lowering medication | ||||||
| Men | 96.9 | 97.1 | 96.8 | 96.5 | 97.6 | 0.924 |
| Women | 96.6 | 94.1 | 97.7 | 94.4 | 98.1 | 0.013 |
| Average | 96.8 | 95.5 | 97.2 | 95.4 | 97.9 | 0.050 |
| Uses of oral hypoglycemic agents | ||||||
| Men | 33.6 | 34.2 | 40.4 | 30.1 | 28.6 | 0.020 |
| Women | 35.3 | 34.3 | 34.1 | 34.1 | 31.9 | 0.904 |
| Average | 34.5 | 34.2 | 37.3 | 32.2 | 30.3 | 0.086 |
| Uses of insulin | ||||||
| Men | 63.3 | 63.0 | 56.8 | 66.5 | 69.0 | 0.021 |
| Women | 61.2 | 60.1 | 63.6 | 60.3 | 66.3 | 0.381 |
| Average | 62.2 | 61.5 | 60.0 | 63.2 | 67.6 | 0.046 |
All analyses adjusted for age and sex (total samples analyses only).
Prevalence of HbA1c below and above 7% among inpatients with type 2 diabetes attaining the Chinese Diabetes Society goals for Prevention and Treatment of Diabetes from 2013 to 2017.
| Year | P value | |||||
|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | ||
| No. of participants | ||||||
| HbA1c < 7% | 163 | 148 | 152 | 227 | 231 | |
| HbA1c ≥ 7% | 444 | 454 | 387 | 512 | 527 | |
| Total | 607 | 602 | 539 | 739 | 758 | |
| Blood pressure <130/80 mmHg | 0.110 | |||||
| HbA1c < 7% | 22.0 | 27.0 | 32.0 | 33.1 | 38.2 | |
| HbA1c ≥ 7% | 78.0 | 73.0 | 68.0 | 66.9 | 61.8 | |
| Normal lipids | 0.042 | |||||
| HbA1c < 7% | 27.9 | 26.7 | 51.1 | 39.3 | 45.2 | |
| HbA1c ≥ 7% | 72.1 | 73.3 | 48.9 | 60.7 | 54.8 | |
| Triglyceride <1.7 mmol/L | 0.010 | |||||
| HbA1c < 7% | 30.0 | 25.6 | 29.7 | 33.0 | 37.2 | |
| HbA1c ≥ 7% | 70.0 | 74.4 | 70.3 | 67.0 | 62.8 | |
| Total cholesterol < 4.5 mmol/L | 0.005 | |||||
| HbA1c < 7% | 30.9 | 25.1 | 32.8 | 34.2 | 40.7 | |
| HbA1c ≥ 7% | 69.1 | 74.9 | 67.2 | 65.8 | 59.3 | |
| Low-density lipoprotein cholesterol <2.6 mmol/L (without CHD)/< 1.8 mmol/L (with CHD) | 0.112 | |||||
| HbA1c < 7% | 28.2 | 28.0 | 35.5 | 36.9 | 37.0 | |
| HbA1c ≥ 7% | 71.8 | 72.0 | 64.5 | 63.1 | 63.0 | |
| High-density lipoprotein cholesterol >1.0 mmol/L (men)/>1.3 mmol/L (women) | 0.078 | |||||
| HbA1c < 7% | 27.1 | 24.6 | 33.5 | 33.6 | 32.7 | |
| HbA1c ≥ 7% | 72.9 | 75.4 | 66.5 | 66.4 | 67.3 | |
All analyses adjusted for age and sex.